Par Health

Highly Engaged Employees

Par Health emerges in 2025 from the strategic merger of Mallinckrodt and Endotwo, combining over a century of expertise in essential medicines. This union leverages the rich heritage of two legacy companies, both founded as family-run businesses committed to integrity and pioneering innovation within the Pharmaceutical and Healthcare sectors. The company's operational foundation is deeply rooted in historical manufacturing sites, reflecting a long-standing dedication to advancing medical solutions.

The company's manufacturing footprint includes the historic API site in St. Louis, Missouri, established over 150 years ago, which remains central to its current operations. Par Health also upholds the legacy of its Rochester, Michigan facility, recognized for producing the first FDA Biologics license for polio vaccine manufacturing. With an employee range of 1,000 - 5,000 employees and a single primary location, the organization is poised for focused growth. Meet Par Health's team to understand the leadership driving these initiatives.

Par Health generates substantial revenue, reported at $1.0B, underscoring its significant market presence. Its primary product offering is "par," serving critical needs within its target industries. The company actively engages in the B2B market, as indicated by its #b2b hashtag, aiming to deliver specialized solutions. This comprehensive approach, blending historical strength with future-oriented strategy, positions Par Health as a key player in the evolving healthcare landscape.